Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).

Fung, A T

Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). [electronic resource] - Eye (London, England) Sep 2012 - 1181-7 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1476-5454

10.1038/eye.2012.174 doi


Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal, Humanized--administration & dosage
Female
Humans
Intravitreal Injections
Male
Pilot Projects
Prospective Studies
Ranibizumab
Single-Blind Method
Subretinal Fluid--metabolism
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Visual Acuity--physiology
Wet Macular Degeneration--diagnosis